ALK and non-small cell lung carcinoma: Brigatinib, another second-generation ALK-TKI, was approved for adult ALK+ metastatic NSCLC in 2020 with a recommended dosage of 90 mg daily for the first 7 days, then increased to 180 mg once daily, based on the ALTA 1L (NCT02737501) trial that targeted advanced ALK+ NSCLC in adult patients who had not previously received an ALK-TKI [103, 104].